과제정보
This study was supported by grants from the National Research Foundation (NRF) funded by the Korean government (grant no. 2015R1A5A1009701 and 2019M3A9H1030682); and, in part by the National Research Foundation of Korea-Grant funded by the Korean Government (Ministry of Science and ICT)-NRF-2017R1A2B2012337. In addition, this paper was written as part of Konkuk University's research support program for its faculty on sabbatical leave in 2019-2020.
참고문헌
- Shah R, Rosso K and Nathanson SD (2014) Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol 5, 283-298 https://doi.org/10.5306/wjco.v5.i3.283
- Ataollahi MR, Sharifi J, Paknahad MR and Paknahad A (2015) Breast cancer and associated factors: a review. J Med Life 8 (Spec Iss 4), 6-11
- Nunziato M, Esposito MV, Starnone F et al (2019) A multigene panel beyond BRCA1/BRCA2 to identify new breast cancer-predisposing mutations by a picodroplet PCR followed by a next-generation sequencing strategy: a pilot study. Anal Chim Acta 1046, 154-162 https://doi.org/10.1016/j.aca.2018.09.032
- Blaschke F, Bruemmer D and Law RE (2004) Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis. Rev Endocr Metab Dis 5, 249-254 https://doi.org/10.1023/B:REMD.0000032413.88756.ee
- Myung DS, Park YL, Kim N et al (2014) Expression of early growth response-1 in colorectal cancer and its relation to tumor cell proliferation and apoptosis. Oncol Rep 31, 788-794 https://doi.org/10.3892/or.2013.2884
- Ma Z, Gao X, Shuai Y et al (2021) EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer. Cell Proliferation 54, e12922 https://doi.org/10.1111/cpr.12922
- Zhao J, Li H and Yuan M (2021) EGR1 promotes stemness and predicts a poor outcome of uterine cervical cancer by inducing SOX9 expression. Genes Genomics 43, 459-470 https://doi.org/10.1007/s13258-021-01064-5
- Ma S, Cheng J, Wang H et al (2021) A novel regulatory loop miR-101/ANXA2/EGR1 mediates malignant characteristics of liver cancer stem cells. Carcinogenesis 42, 93-104 https://doi.org/10.1093/carcin/bgaa055
- Mohamad T, Kazim N, Adhikari A, Davie JK (2018) EGR1 interacts with TBX2 and functions as a tumor suppressor in rhabdomyosarcoma. Oncotarget 9, 18084-18098 https://doi.org/10.18632/oncotarget.24726
- Wei LL, Wu XJ, Gong CC and Pei DS (2017) Egr-1 suppresses breast cancer cells proliferation by arresting cell cycle progression via down-regulating CyclinDs. Int J Clin Exp Patho 10, 10212-10222
- Baron V, Adamson ED, Calogero A, Ragona G and Mercola D (2006) The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 13, 115-124 https://doi.org/10.1038/sj.cgt.7700896
- Ferraro B, Bepler G, Sharma S, Cantor A and Haura EB (2005) EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 23, 1921-1926 https://doi.org/10.1200/JCO.2005.08.127
- Zhang HH, Chen XJ, and Wang JK et al (2014) EGR1 decreases the malignancy of human non-small cell lung carcinoma by regulating KRT18 expression. Sci Rep 4, 5416 https://doi.org/10.1038/srep05416
- Min IM, Pietramaggiori G, Kim FS, Passegue E, Stevenson KE and Wagers AJ (2008) The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell 2, 380-391 https://doi.org/10.1016/j.stem.2008.01.015
- Chen DG, Zhu B, Lv SQl et al (2017) Inhibition of EGR1 inhibits glioma proliferation by targeting CCND1 promoter. J Exp Clin Canc Res 36, 186 https://doi.org/10.1186/s13046-017-0656-4
- Tao WW, Shi JF, Zhang Q, Xue B, Sun YJ and Li CJ (2013) Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner. Biomed Pharmacother 67, 197-202 https://doi.org/10.1016/j.biopha.2013.01.001
- Wong KM, Song J and Wong YH (2021) CTCF and EGR1 suppress breast cancer cell migration through transcriptional control of Nm23-H1. Sci Rep 11, 491 https://doi.org/10.1038/s41598-020-79869-9
- Hao L, Huang F, Yu X et al (2021) The role of early growth response family members 1-4 in prognostic value of breast cancer. Front Genet 12, 809
- Shajahan-Haq AN, Boca SM, Jin L et al (2017) EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer. Oncotarget 8, 96865-96884 https://doi.org/10.18632/oncotarget.18292
- Rhodes DR, Kalyana-Sundaram S, Mahavisno V et al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166-180 https://doi.org/10.1593/neo.07112
- Rhodes DR, Yu J, Shanker K et al (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6 https://doi.org/10.1016/s1476-5586(04)80047-2
- Saha SK, Jeong Y, Cho S and Cho SG (2018) Systematic expression alteration analysis of master reprogramming factor OCT4 and its three pseudogenes in human cancer and their prognostic outcomes. Sci Rep 8, 14806 https://doi.org/10.1038/s41598-018-33094-7
- Saha SK, Kim KE, Islam SMR, Cho SG and Gil M (2019) Systematic multiomics analysis of alterations in C1QBP mRNA expression and relevance for clinical outcomes in cancers. J Clin Med 8, 513 https://doi.org/10.3390/jcm8040513
- Chandrashekar DS, Bashel B, Balasubramanya SAH et al (2017) UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649-658 https://doi.org/10.1016/j.neo.2017.05.002
- Goldman MJ, Craft B, Hastie M et al (2020) Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol 38, 675-678 https://doi.org/10.1038/s41587-020-0546-8
- Uhlen M, Zhang C, Lee S et al (2017) A pathology atlas of the human cancer transcriptome. Science 357, eaan2507 https://doi.org/10.1126/science.aan2507
- Uhlen M, Fagerberg L, Hallstrom BM et al (2015) Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 https://doi.org/10.1126/science.1260419
- Crowe AR and Yue W (2019) Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: an integrated protocol. Bio Protoc 9, e3465
- Diez-Villanueva A, Mallona I and Peinado MA (2015) Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetics Chromatin 8, 22 https://doi.org/10.1186/s13072-015-0014-8
- Saha SK, Islam S, Abdullah-AL-Wadud M, Islam S, Ali F and Park KS (2019) Multiomics analysis reveals that GLS and GLS2 differentially modulate the clinical outcomes of cancer. J Clin Med 8, 355 https://doi.org/10.3390/jcm8030355
- Tate JG, Bamford S, Jubb HC et al (2019) COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res 47, D941-D947 https://doi.org/10.1093/nar/gky1015
- Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multi-dimensional cancer genomics data. Cancer Discov 2, 401-404 https://doi.org/10.1158/2159-8290.CD-12-0095
- Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, p11
- Mizuno H, Kitada K, Nakai K and Sarai A (2009) Progno-Scan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2, 18 https://doi.org/10.1186/1755-8794-2-18
- Nagy A, Lanczky A, Menyhart O and Gyorffy B (2018) Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 8, 9227 https://doi.org/10.1038/s41598-018-27521-y
- Goldman M, Craft B, Hastie M, Repecka K, Kamath A, McDade F (2019) The UCSC Xena platform for cancer genomics data visualization and interpretation. BioRxiv 326470, doi: https://doi.org/10.1101/326470
- Jezequel P, Frenel JS, Campion L et al (2013) bc-GenEx-Miner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database 2013, bas060 https://doi.org/10.1093/database/bas060
- Havis E and Duprez D (2020) EGR1 transcription factor is a multifaceted regulator of matrix production in tendons and other connective tissues. Int J Mol Sci 21, 1664 https://doi.org/10.3390/ijms21051664
- Magee N and Zhang Y (2017) Role of early growth response 1 in liver metabolism and liver cancer. Hepatoma Res 3, 268 https://doi.org/10.20517/2394-5079.2017.36
- Lohoff M, Giaisi M, Kohler R, Casper B, Krammer PH and Li-Weber M (2010) Early growth response protein-1 (Egr-1) is preferentially expressed in T helper type 2 (Th2) cells and is involved in acute transcription of the Th2 cytokine interleukin-4. J Biol Chem 285, 1643-1652 https://doi.org/10.1074/jbc.M109.011585
- Milbrandt J (1987) A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 238, 797-799 https://doi.org/10.1126/science.3672127
- Duclot F and Kabbaj M (2017) The role of early growth response 1 (EGR1) in brain plasticity and neuropsychiatric disorders. Front Behav Neurosci 11, 35 https://doi.org/10.3389/fnbeh.2017.00035
- Thiel G and Cibelli G (2002) Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193, 287-292 https://doi.org/10.1002/jcp.10178
- Egerod FL, Bartels A, Fristrup N et al (2009) High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression. BMC Cancer 9, 385 https://doi.org/10.1186/1471-2407-9-385
- Gitenay D and Baron VT (2009) Is EGR1 a potential target for prostate cancer therapy? Future Oncol 5, 993-1003 https://doi.org/10.2217/fon.09.67
- Lin M, Huang J, Jiang X et al (2016) A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/131 I-antiAFPMcAb-GCV/MFH. Sci Rep 6, 33524 https://doi.org/10.1038/srep33524
- Ma J, Ren Z, Ma Y et al (2009) Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-κB synergy. J Biol Chem 284, 34600-34606 https://doi.org/10.1074/jbc.M109.016246
- Maegawa M, Arao T, Yokote H et al (2009) EGFR mutation up-regulates EGR1 expression through the ERK pathway. Anticancer Res 29, 1111-1117
- Adamson E, de Belle I, Mittal S et al (2003) Egr1 signaling in prostate cancer. Cancer Biol Ther 2, 617-622
- Curtis C, Shah SP, Chin S-F et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 https://doi.org/10.1038/nature10983
- Liu J, Liu YG, Huang R et al (2007) Concurrent down-regulation of Egr-1 and gelsolin in the majority of human breast cancer cells. Cancer Genomics Proteomics 4, 377-385
- Yamashita K, Upadhyay S, Osada M et al (2002) Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2, 485-495 https://doi.org/10.1016/S1535-6108(02)00215-5
- Ng JMK and Yu J (2015) Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci 16, 2472-2496 https://doi.org/10.3390/ijms16022472
- Richter AM, Walesch SK and Dammann RH (2016) Aberrant promoter methylation of the tumour suppressor RASSF10 and its growth inhibitory function in breast cancer. Cancers 8, 26 https://doi.org/10.3390/cancers8030026
- Martincorena I and Campbell PJ (2015) Somatic mutation in cancer and normal cells. Science 349, 1483-1489 https://doi.org/10.1126/science.aab4082
- Myung E, Park YL, Kim N et al (2013) Expression of early growth response-1 in human gastric cancer and its relationship with tumor cell behaviors and prognosis. Pathol Res Pract 209, 692-699 https://doi.org/10.1016/j.prp.2013.08.001
- Kataoka F, Tsuda H, Arao T et al (2012) EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy. Genes Chromosomes Cancer 51, 300-312 https://doi.org/10.1002/gcc.21916
- Boulding T, Wu F, McCuaig R et al (2016) Differential roles for DUSP family members in epithelial-to-mesenchymal transition and cancer stem cell regulation in breast cancer. PLoS One 11, e0148065 https://doi.org/10.1371/journal.pone.0148065
- Chen FM, Chang HW, Yang SF et al (2012) The mitogen-activated protein kinase phosphatase-1 (MKP-1) gene is a potential methylation biomarker for malignancy of breast cancer. Exp Mol Med 44, 356-362 https://doi.org/10.3858/emm.2012.44.5.040
- Shen Q and Brown PH (2003) Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 8, 45-73 https://doi.org/10.1023/A:1025783221557
- Wagstaff SC, Bowler WB, Gallagher JA and Hipskind RA (2000) Extracellular ATP activates multiple signalling pathways and potentiates growth factor-induced c-fos gene expression in MCF-7 breast cancer cells. Carcinogenesis 21, 2175-2181 https://doi.org/10.1093/carcin/21.12.2175
- Fisler DA, Sikaria D, Yavorski JM, Tu YPN and Blanck G (2018) Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome. Oncol Lett 16, 2757-2763
- Shen JL, Zhang YP, Yu H et al (2016) Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy. Cancer Med 5, 2061-2068 https://doi.org/10.1002/cam4.772
- Fang J, Ye ZM, Gu FY et al (2018) DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system. Oncol Lett 16, 1869-1875
- Lu CH, Shen Q, DuPre E, Kim H, Hilsenbeck S and Brown PH (2005) cFos is critical for MCF-7 breast cancer cell growth. Oncogene 24, 6516-6524 https://doi.org/10.1038/sj.onc.1208905
- Langer S, Singer CF, Hudelist G et al (2006) Jun and Fos family protein expression in human breast cancer: Correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol 27, 345-352
- Park JA, Na HH, Jin HO and Kim KC (2019) Increased expression of fosb through reactive oxygen species accumulation functions as pro-apoptotic protein in Piperlongumine Treated MCF7 breast cancer cells. Mol Cells 42, 884-892 https://doi.org/10.14348/molcells.2019.0088
- Huang Y-T, Lan Q, Lorusso G, Duffey N and Ruegg C (2017) The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis. Oncotarget 8, 9200-9215 https://doi.org/10.18632/oncotarget.13677
- Hellinger JW, Huchel S, Goetz L, Bauerschmitz G, Emons G and Grundker C (2019) Inhibition of CYR61-S100A4 axis limits breast cancer invasion. Front Oncol 9, 1074 https://doi.org/10.3389/fonc.2019.01074